Sept. 25, 2015
Below are current clinical trials.47 studies in Lung cancer
(open studies only).
Filter this list of studies by location, status and more.
This is a Phase 1b, open label, multi-center study of CMB305 (sequentially administered LV305 [a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene] and G305 [NY-ESO-1 recombinant protein plus GLA-SE]) in patients with melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1. CMB305 is a novel in vivo approach designed to stimulate the body's immune system to fight the spread and growth of cancer for patients whose tumors express the NY-ESO-1 protein. LV305 will be given in a prime-boost approach with G305 to induce a synergistic immunotherapeutic response.
The purpose of this study is to collect medical and personal histories, blood and/or tumor tissue samples from patients who are long-term survivors of lung cancer. This study will help us to develop better ways to provide care and advice, develop better treatments to minimize long-term side effects, and improve the quality of life and outcome of lung cancer patients. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing or dying of lung cancer.
We are evaluating interleukin-33 and innate lymphoid cells in non-small cell lung cancer to further explain underlying mechanisms and assess their potential as prognostic biomarkers and targets in treatment.
The primary objective of this proposal is to develop a Thoracic Specimen Registry at Mayo Clinic. The purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of HBI-8000 when combined with a standard dose and regimen of nivolumab.
The purpose of this study is to determine the safety and effectiveness of ceritinib when combined with nivolumab for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer patients.
This phase I trial studies the best dose and side effects of AR160 in treating patients with B-cell non-Hodgkin lymphoma that has come back or is not responding to treatment. AR160 is a combination of paclitaxel albumin-stabilized nanoparticle formulation and rituximab. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel albumin-stabilized nanoparticle formulation and rituximab may work better in treating patients with B-cell non-Hodgkin lymphoma.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC). ED SCLC is defined herein as any SCLC except a disease confined to the hemithorax of origin, with or without the involvement of regional lymph nodes, including ipsilateral and contralateral mediastinal, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular nodes
- Non-small cell lung cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Aug. 27, 2015.
- Estimated new cancer cases and deaths by sex, U.S., 2015. American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index. Accessed Aug. 27, 2015.
- Small cell lung cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Aug. 27, 2015.
- Niederhuber JE, et al., eds. Cancer of the lung. Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Aug. 27, 2015.
- What you need to know about lung cancer. National Cancer Institute. http://www.cancer.gov/publications/patient-education/wyntk-lung-cancer. Accessed Aug. 27, 2015.
- Lung cancer prevention (PDQ). National Cancer Institute. http://www.cancer.gov/types/lung/patient/lung-prevention-pdq. Accessed Aug. 27, 2015.
- Aberle DR, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine. 2011;365:395.
- Detterbeck FC, et al. Diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl):7S.
- AskMayoExpert. Non-small cell lung cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- AskMayoExpert. Small cell lung cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Cook AJ. Decision Support System. Mayo Clinic, Rochester, Minn. March 17, 2015.
- Cairns LM. Managing breathlessness in patients with lung cancer. Nursing Standard. 2012;27:44.
- Taking time: Support for people with cancer. National Cancer Institute. http://www.cancer.gov/publications/patient-education/taking-time. Accessed Aug. 27, 2015.
- Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. New England Journal of Medicine. 2010;363:733.